Pointing to the potential usefulness of genetic tests and therapeutics in patient care, the American Medical Association is calling for greater transparency and more standardized guidelines for payer coverage. READ MORE
New guidelines from the National Comprehensive Cancer Network now advise that phsycians take a more active role in discussing sexual dysfunction with their patients.
After a review of recent findings and US Food and Drug Administration approvals, the National Comprehensive Cancer Network has made some major changes to its guidelines for multiple myeloma.
Pointing to the potential usefulness of genetic tests and therapeutics in patient care, the American Medical Association is calling for greater transparency and more standardized guidelines for payer coverage.
The National Comprehensive Cancer Network is partnering with a health care decision support company to integrate their clinical practice guidelines into a technological resource for point-of-care access and treatment recommendations.
A new clinical pathway has been designed and implemented to improve colon and rectal surgical procedures and enhance successful patient recovery.
McKesson Specialty Health and The US Oncology Network have expanded their agreement with the National Comprehensive Cancer Network to add five new disease states to Value Pathways.
Research in Review
The National Comprehensive Cancer Network agreed that ongoing monitoring and research regarding financial conflicts of interest at the interface of academia, medicine, and industry is critical, according a letter published in JAMA Oncology.
A new study that quantifies industry financial conflicts of interest (FCOIs) found that nearly nine out of 10 physicians and researchers who helped develop the National Comprehensive Network (NCCN) guidelines reported financial ties to the pharmaceutical and medical device industries.
European Society of Cardiology has published a novel position paper tackling the problem of cardiac toxicity associated with anticancer therapies.
A team of researchers is recommending an overhaul of the process that determines which cancer drugs used off-label are reimbursed by federally-funded health insurance in the United States.